文献速递胸部肿瘤

ROS1酪氨酸激酶抑制剂的综合评述:按结构设计与突变谱(溶剂前沿突变G2032R与中央β折叠6突变L2086F)分类

Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).
PubMed 文献 · J Thorac Oncol · 2023-12-07

ROS1融合阳性NSCLC约占NSCLC的1%至2%,除已批准的克唑替尼、恩曲替尼和瑞普替尼外,多种ROS1酪氨酸激酶抑制剂(TKI)正在研发。本文按结构(环状与非环状)及对溶剂前沿突变G2032R或中央β折叠6(Cβ6)突变L2086F的抑制能力对ROS1 TKI分类,并总结其已报告的临床活性,为不同临床情境下如何使用这些药物提供参考。

要点

  • ROS1融合阳性NSCLC约占NSCLC的1%至2%,已批准ROS1 TKI为克唑替尼、恩曲替尼和瑞普替尼。
  • Cβ6突变ROS1 L2086F可导致对瑞普替尼、他雷替尼及潜在NVL-520等下一代ROS1 TKI耐药。
  • 已发表患者报告显示卡博替尼可克服L2086F耐药,色瑞替尼和吉列替尼等L型I类ROS1 TKI具临床前抗ROS1活性。

核心结论

  • 按结构(环状与非环状)及对G2032R或L2086F的抑制能力对ROS1 TKI分类,可为其在不同临床情境下的使用提供参考。
  • Cβ6突变ROS1 L2086F对瑞普替尼、他雷替尼及潜在NVL-520等下一代ROS1 TKI耐药,已发表患者报告显示卡博替尼可克服该耐药。
  • 色瑞替尼和吉列替尼等L型I类ROS1 TKI在临床前对ROS1(及ALK)具活性,可能克服L2086F耐药。
  • 未来临床试验应研究卡博替尼和吉列替尼,将其重新定位为可靶向ROS1 L2086F Cβ6突变的ROS1 TKI。

研究设计与样本

  • 综合评述,按结构(环状与非环状)及抑制能力(对G2032R或L2086F)对ROS1 TKI分类,并总结已报告的临床活性。

主要发现

  • ROS1融合阳性NSCLC约占NSCLC的1%至2%,除克唑替尼、恩曲替尼和瑞普替尼外,多种ROS1 TKI正在研发。
  • Cβ6突变ROS1 L2086F对瑞普替尼、他雷替尼及潜在NVL-520等下一代ROS1 TKI赋予耐药。
  • 已发表患者报告记录卡博替尼可克服L2086F耐药,色瑞替尼和吉列替尼等L型I类ROS1 TKI在临床前对ROS1(及ALK)具活性。
  • 吉列替尼已获批作为FLT3抑制剂用于复发难治性FLT3阳性急性髓系白血病。

关键数值与推荐

  • ROS1融合阳性NSCLC约占NSCLC的1%至2%。
  • 已批准的ROS1 TKI为克唑替尼、恩曲替尼和瑞普替尼。
  • Cβ6突变ROS1 L2086F对瑞普替尼、他雷替尼及潜在NVL-520耐药,卡博替尼在已发表患者报告中可克服该耐药。
  • 色瑞替尼和吉列替尼等L型I类ROS1 TKI在临床前对ROS1(及ALK)具活性。

临床怎么用

  • 原文按结构及对G2032R或L2086F的抑制能力对ROS1 TKI分类,旨在为不同临床情境下如何使用这些药物提供参考。
  • 作者指出未来临床试验应研究卡博替尼和吉列替尼,将其重新定位为可靶向ROS1 L2086F Cβ6突变的ROS1 TKI。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite ROS1 fusion-positive NSCLC accounting for approximately 1% to 2% of NSCLC, there is a long list of ROS1 tyrosine kinase inhibitors (TKIs) being developed in addition to three approved ROS1 TKIs, crizotinib, entrectinib and repotrectinib. Here, we categorized ROS1 TKIs by their structures (cyclic versus noncyclic) and inhibitory abilities (active against solvent front mutation G2032R or central β-sheet #6 [Cβ6] mutation L2086F) and summarized their reported clinical activity in order to provide a dashboard on how to use these ROS1 TKIs in various clinical situations. In addition, the less known Cβ6 mutation ROS1 L2086F confer resistances to next-generation ROS1 TKIs (repotrectinib, taletrectinib, and potentially NVL-520) that can be overcome by cabozantinib as documented in published patient reports and potentially by certain L-shaped type I ROS1 TKIs including ceritinib and gilteritinib, which is approved as a FLT3 inhibitor for relapsed refractory FLT3+ acute myeloid leukemia but have published preclinical activites against ROS1 (and ALK). Future clinical trials should investigate cabozantinib and gilteritinib to repurpose them as ROS1 TKIs that can target ROS1 L2086F Cβ6 mutation.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ou SI, Hagopian GG, Zhang SS, et al. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]). J Thorac Oncol. 2023. PMID: 38070596. doi:10.1016/j.jtho.2023.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。